Angela Wheeler, MD
Sports Medicine · Chesterton, INNPI 1932262847
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 234 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations.
Across 234 payments — averaging $26.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$872
- Novo Nordisk$857
- Abbott$478
- Lilly USA, LLC$415
- Abiomed$261
- plus $2K from 30 others
What the payments were for
- Food & beverage$6,22699%
- Education$681%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 35 | $1,294 |
| AbbVie | 42 | $872 |
| Novo Nordisk | 50 | $857 |
| Abbott | 13 | $478 |
| Lilly USA, LLC | 17 | $415 |
| Abiomed | 5 | $261 |
| Astellas Pharma US Inc | 10 | $244 |
| Vifor Pharma, Inc. | 3 | $216 |
| Pfizer | 5 | $191 |
| Boehringer Ingelheim | 4 | $164 |
| Bayer | 4 | $161 |
| Coloplast | 1 | $127 |
| Neurocrine Biosciences, Inc. | 1 | $122 |
| Acell, Inc. | 1 | $108 |
| Xeris Pharmaceuticals, Inc. | 5 | $96 |
| Hologic Sales And Service, LLC | 3 | $71 |
| Exact Sciences | 4 | $68 |
| Lupin Inc. | 4 | $57 |
| Mayne Pharma Commercial LLC | 2 | $54 |
| Dexcom, Inc. | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Agile Therapeutics, Inc. | 2 | $42 |
| Amgen | 2 | $32 |
| Eisai Inc. | 2 | $32 |
| Shield Therapeutics Inc | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Bard Access Systems, Inc. | 1 | $20 |
| Organon | 1 | $20 |
| KCI USA, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Exeltis, USA Inc. | 1 | $18 |
| Pacira Pharmaceuticals Incorporated | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Mylan Pharmaceuticals Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,294 in reported general payments places this provider in the 75th percentile of 156 sports medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 55 | $68,546 |
| EliquisApixaban | 52 | $55,207 |
| JanuviaSitagliptin Phosphate | 36 | $53,714 |
| RybelsusSemaglutide | 19 | $32,742 |
| TrulicityDulaglutide | 18 | $19,230 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $3,201 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 140 | $2,382 |
| Gabapentin | 114 | $2,042 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 19 | $1,654 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,437 |
| Losartan Potassium | 228 | $1,361 |
| Amlodipine Besylate | 346 | $1,279 |
| SynthroidLevothyroxine Sodium | 15 | $1,118 |
| Atorvastatin Calcium | 207 | $1,053 |
| Tolterodine Tartrate ErTolterodine Tartrate | 20 | $947 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $857 | $101,28974 claims |
| PfizerEliquis | $191 | $55,20752 claims |
| Lilly USA, LLCTrulicity | $415 | $19,23018 claims |
| AbbVieSynthroid | $872 | $1,11815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 156 sports medicine providers in Indiana.
Other sports medicine in Chesterton
- Jorge ChahlaMunster$917K
- Sean CallowayGreenwood$130K
- Ryan NixonGreenwood$62K
- Tyler McCarrollCarmel$60K
- Nedal AlkhatibIndianapolis$51K
- Stephen ShivelyGreenfield$51K
- Dale SneadCarmel$45K
- Gregory FoxBloomington$37K
- Gregory WynneNoblesville$36K
- Brian WisselLawrenceburg$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.